New product intros (adalimumab (new indication), docaravimab and miromavimab, empagliflozin/linagliptin/metformin hydrochloride (new combination), enarodustat, filgotinib, fluticasone propionate/formoterol fumarate/glycopyrronium (new combination), oliceridine, sofpironium bromide, tafasitamab-cxix,

{"title":"New product intros (adalimumab (new indication), docaravimab and miromavimab, empagliflozin/linagliptin/metformin hydrochloride (new combination), enarodustat, filgotinib, fluticasone propionate/formoterol fumarate/glycopyrronium (new combination), oliceridine, sofpironium bromide, tafasitamab-cxix,","authors":"","doi":"10.1358/dot.2021.57.1.3265445","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2021.57.1.3265445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
新产品简介(阿达木单抗(新适应症)、多卡韦单抗和莫洛马韦单抗、恩帕列嗪/利格列汀/盐酸二甲双胍(新组合)、埃那罗司他、非戈替尼、丙酸氟替卡松/富马酸福莫特罗/格隆吡隆(新组合,
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信